RU 486 inhibits peripheral effects of glucocorticoids in humans.
RU 486 [17 beta-hydroxy-11 beta-(4-dimethylaminophenyl)17 alpha-(prop-1-ynyl)estra-4,9-dien-3-one] is a synthetic steroid receptor antagonist. To evaluate the peripheral antiglucocorticoid action of this compound, we investigated its ability to antagonize cutaneous steroid-induced vasoconstriction. This phenomenon, produced by three different topical steroids in six normal men, was consistently and significantly attenuated or abolished by oral administration of 6 mg/kg RU 486. This demonstration of a peripheral action of RU 486 is important in relation to the potential therapeutic use of this well tolerated drug in states of hypercortisolism. It also indicates that the cutaneous vasoconstrictor effects of topical steroids are mediated by occupancy of glucocorticoid receptors.
D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D001623:Betamethasone / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D002990:Clobetasol / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D004311:Double-Blind Method; D004963:Estrenes / Q000494:pharmacology*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D015735:Mifepristone; D011897:Random Allocation; D011965:Receptors, Glucocorticoid / Q000502:physiology; D012867:Skin / Q000098:blood supply; D014661:Vasoconstriction / Q000187:drug effects*
D000893:Anti-Inflammatory Agents; D004963:Estrenes; D011965:Receptors, Glucocorticoid; D015735:Mifepristone; C011175:betamethasone-17,21-dipropionate; C010893:clobetasone butyrate; D001623:Betamethasone; D002990:Clobetasol; D006854:Hydrocortisone